Kyverna Therapeutics Inc (KYTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Operating Expenses | 41,367 | 39,282 | 38,727 | 44,410 | 47,408 |
| Operating Income | -41,367 | -39,282 | -38,727 | -44,410 | -47,408 |
| Interest Expense | 667 | 443 | 7 | 14 | 25 |
| Other Income | 2,306 | 1,921 | 1,947 | 2,343 | 2,798 |
| Pre-tax Income | -39,728 | -37,804 | -36,787 | -42,081 | -44,635 |
| Net Income Continuous | -39,728 | -37,804 | -36,787 | -42,081 | -44,635 |
| Net Income | $-39,728 | $-37,804 | $-36,787 | $-42,081 | $-44,635 |
| EPS Basic Total Ops | -0.66 | -0.79 | -0.85 | -0.97 | -1.03 |
| EPS Basic Continuous Ops | -0.66 | -0.79 | -0.85 | -0.97 | -1.03 |
| EPS Diluted Total Ops | -0.66 | -0.79 | -0.85 | -0.97 | -1.03 |
| EPS Diluted Continuous Ops | -0.66 | -0.79 | -0.85 | -0.97 | -1.03 |
| EPS Diluted Before Non-Recurring Items | N/A | -0.80 | -0.85 | -0.97 | -1.03 |
| EBITDA(a) | $-41,016 | $-38,914 | $-38,312 | $-43,895 | $-46,907 |